EGFR EGFR EGFR Bio-Marker Composition for Sensitivity Prediction of EGFR Drug Estimation Method for Sensitivity Prediction of EGFR Drug using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Sensitivity Prediction of EGFR Drug

摘要

The present invention relates to a biomarker composition for determining EGFR drug reactivity using a cancer biomarker labeling scan which is a novel learning model, capable of reliable prediction and drug labeling of EGFR drug reactivity by predicting a haplotype biomarker including EGFR drug reactivity function information. For determining the reactivity to an EGFR drug, the biomarker composition composed of a combination of markers containing a variation that modulates gene expression comprises 9_111597344_C_A (marker 1) and 18_47115026_C_T (marker 2). According to the present invention, through biomarkers for drugs related to EGFR, it is possible to predict the susceptibility of each target genotype for an EGFR drug, and thus effective preliminary verification is conducted not only in the field of personalized medicine but also in the discovery of new drug candidates.